Evidence map›Paper›PMID 41994995›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Associations of

Mahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, Carles Falcon, David López-Martos, Gonzalo Sánchez-Benavides, Anna Brugulat-Serrat, Aida Niñerola-Baizán, Nicholas J Ashton, Thomas K Karikari and 23 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Mahnaz ShekariBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Armand González EscalanteBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Marta Milà-AlomàBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Carles FalconBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
David López-MartosBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Gonzalo Sánchez-BenavidesBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Anna Brugulat-SerratBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Aida Niñerola-BaizánCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina; (CIBERBBN), Instituto de Salud Carlos III, Madrid, Spain.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Thomas K KarikariDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Juan Lantero-RodriguezDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Laia Montoliu-GayaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Anniina SnellmanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Theresa A DayLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
Jeffrey L DageStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paula Ortiz-RomeroBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Matteo ToniettoF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Edilio BorroniF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Gregory KleinF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Margherita CarboniRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Clara Quijano-RubioRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Eugeen VanmechelenADx NeuroSciences, Ghent, Belgium.
Carolina MinguillónBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Karine FauriaBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Andrés PerissinottiCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina; (CIBERBBN), Instituto de Salud Carlos III, Madrid, Spain.
José Luis MolinuevoBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
Oriol Grau-RiveraBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Marc Suárez-CalvetBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.ORCID 0000-0002-6155-0642
ALFA Study

Funding

Alzheimer's AssociationConsell Català de Recerca i Innovació 2021 SGR 00913F. Hoffmann-La Roche'la Caixa' Foundation LCF/PR/SC22/68000001Tribeka Imaging Platform Project
6 · The paper itself

Abstract

introductionWe examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques, fluid biomarkers, and cognition in early preclinical Alzheimer's disease (AD).

methodsWe analyzed 97 participants from the ALFA+ cohort with tau and amyloid PET, magnetic resonance imaging, fluid biomarkers (cerebrospinal fluid [CSF]/plasma), and cognitive data. Braak staging was applied, and correlations with biomarkers and cognitive measures were assessed. Receiver operating characteristic analyses evaluated biomarker performance in predicting tau PET positivity

resultsCSF and plasma tau phosphorylated at threonine 217 (p-tau217) showed the strongest correlation with early Braak I/II tau PET signal (r = 0.58, and r = 0.37, respectively), while plasma p-tau181 and p-tau181/Aβ42 showed moderate associations (r ∼ 0.25). However, positive predictive values were low (PPV = 0.09-0.33). DISCUSSION:

Indexed as

Alzheimer DiseaseCognitionPositron-Emission Tomographytau ProteinsAgedAmyloid beta-PeptidesBiomarkersBrainFemaleFluorine RadioisotopesHumansMagnetic Resonance ImagingMaleNeurofibrillary TanglesPlaque, AmyloidAmyloid beta-PeptidesBiomarkersFluorine RadioisotopesMAPT protein, humantau Proteins18 < /u > f‐ro‐948 petAlzheimer's diseasefluid biomarkersneurofibrillary tangle (NFT)tau pathology

Identifiers

PMID41994995
PMCPMC13088146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.